[go: up one dir, main page]

EP0229155A1 - Complexe pharmaceutique et composition pour empecher la chute descheveux - Google Patents

Complexe pharmaceutique et composition pour empecher la chute descheveux

Info

Publication number
EP0229155A1
EP0229155A1 EP86904524A EP86904524A EP0229155A1 EP 0229155 A1 EP0229155 A1 EP 0229155A1 EP 86904524 A EP86904524 A EP 86904524A EP 86904524 A EP86904524 A EP 86904524A EP 0229155 A1 EP0229155 A1 EP 0229155A1
Authority
EP
European Patent Office
Prior art keywords
surfactant polymer
polyoxyethylene glycol
complex
polymer
glycol derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86904524A
Other languages
German (de)
English (en)
Other versions
EP0229155A4 (en
Inventor
Laszlo L. Darko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FARMACON Inc
Original Assignee
FARMACON Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FARMACON Inc filed Critical FARMACON Inc
Publication of EP0229155A1 publication Critical patent/EP0229155A1/fr
Publication of EP0229155A4 publication Critical patent/EP0229155A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993Derivatives containing from 2 to 10 oxyalkylene groups

Definitions

  • This application is concerned with a pharmaceutically active complex useful to inhibit hair loss from the human scalp. More particularly, it is concerned with the complexes formed by reaction between allyl isothiocyanate and certain polyoxyalkylene glycols, with pharmaceutical compositions containing such complexes and with the use of the complexes to protect against loss of human hair.
  • Polyoxyalkylene glycols are a well known class of surfactant polymers. They are ethers formed by the polymerization of selected • glycols. They are available in a variety of forms. Often they will carry other functional groups.
  • the surfactant polymers useful in the practice of this invention will have a molecular weight of from 500 to 10,000, and the alkylene group will have 2 or 3 carbon atoms.
  • Specific surfactant polymers useful in the practice of the invention may include copolymers derived from glycols with two or three carbon atoms in the alkylene groups.
  • One class of surfactant polymers useful in the invention is available under the trademark Pluronic from BASF-Wyandotte.
  • the class includes polyoxypropylene glycols.
  • Tweens are polyoxyethylene glycol derivatives of fatty acid partial esters of sorbiton anhydrides. Amongst the most useful of the Tweens for the practice of this invention are polyoxyethylene glycol derivatives of sorbitan laurate, stearate, palmitate and oleate having molecular weights from 500 to 10,000.
  • Still another useful class of polyoxyalkylene glycol derivatives is available from Union Carbide Corp. under the trademark Carbowax.
  • ITC allyl isothiocyanate
  • polyoxyethylene glycols at a temperature of from about 20 C to 60 C for a period of from about 0.5 to 30 hours, a complex will form.
  • the ratio of ITC to surfactant polymer will depend upon the amounts of reactants employed. For the practice of this invention, the ratio of ITC to surfactant polymer is from about 1:1 to 1:20.
  • the preferred solvents for the reaction are water and alkanols containing up to three carbon atoms. Ethanol and isopropanol are the preferred alkanols. Mixtures of solvents can be employed.
  • the complex wil be utilized in the solvent mixture in which it is prepared, or the solvent mixture can be combined or blended with other carriers to form creams, lotions and the like. It is also convenient to utilize the solvent mix containing the dissolved complex to form shampoos which, for the purpose of this description and claims can be regarded as pharmaceutical compositions.
  • SUBSTITUTE SHEET The complex need not be isolated. Its presence in the solution can be readily determined by the change in the infrared pattern between the original and final mixtures.
  • the formation of the complexes can also be established by the fact that the rate of diffusion of the ITC is different from the rate of diffusion of the complex through cellophane into the same solvent in which the complex is prepared.
  • the diffusion constants for certain samples are as follows:
  • the first listed diffusion constant is for ITC alone.
  • the second is for the complex that is formed after reaction between Tween 80 and ITC.
  • Tween 80 is polyoxyethylene sorbitan monooleate.
  • the diffusion rates were determined by the Drobnica method [Drobnica, Kanppova: Chem. Zvesti, 27 799 (1973)].
  • the test material as prepared in a solvent was placed in a cellophane dialysis cell and the cell suspended in 10 times its volume of the same solvent. Aliquots were removed at selected time intervals from the solvent outside the cell and reacted to form thioglycols as a measure of the amount diffused.
  • the complexes can be used in any of a variety of compositions including liquids, creams, lotions, emollients or other compositions generally employed for topical application.
  • Useful compositions will contain from about 0.01% to 10% by weight of active complex based on the total weight of the composition.
  • the compositions may contain other ingredients such as antiseptics, germicides or anti- dandruff compounds.
  • compositions containing the complex when applied directly to the human scalp will inhibit hair loss.
  • the preparation made according to Example 7 was tested with 30 different human subjects with a hair loss problem.
  • the carrier of Example 7 without the complex was tested on 32 additional human subjects also suffering hair loss.
  • the mixtures were applied by vigorous rubbing morning and evening for 30 consecutive days. Determination of the product effect was carried out by measuring the newly grown hair length, diameter and cuticle by light microscopy. The results are shown in the following table.
  • Example 2 To 100 ml. of a 1.8:1 ethanol-water solution containing 0.00897 M ITC is added a solution of 0.0089 M Carbowax-6000 and the procedure of Example 1 is followed.
  • the ITC:polymer ratio is 1:1.
  • the concentration of the complex in the composition is approximately 5.3% by weight.
  • Example 1 To 100 ml. of a 1.8:1. ethanol-water solution containing 0.00897 M ITC is added a solution of 0.0045 M Tween-80 and the procedure of Example 1 is followed to prepare a complex in which the molar ratio of ITC to polymer is 2:1 and the concentration of the complex in the composition is about 0.7% by weight.
  • Example 5 To 100 ml. of a 1.8:1 ethanol-water solution containing 0.00449 M ITC is added a solution of 0.0049 M Carbowax-6000 and the procedure of Example 5 is followed. The mole ratio of ITC to polymer ratio is 1:1. The concentration of the complex in the composition is about 5%.
  • Example 5 To 100 ml. of alcohol-water solution containing 0.00897 M ITC is added a solution of 0.0179 M Tween-80 and then the procedure described in Example 5 is followed. The ITC to polymer mole ratio is 1:1.9. The concentration of the complex in the composition is about 4.6%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Complexes d'isothiocyanate allylique et glycoles de polyoxyalcènedestinés à empêcher la chute des cheveux.
EP19860904524 1985-06-20 1986-06-16 Pharmaceutical complex and composition to inhibit hair loss Withdrawn EP0229155A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74696485A 1985-06-20 1985-06-20
US746964 1985-06-20

Publications (2)

Publication Number Publication Date
EP0229155A1 true EP0229155A1 (fr) 1987-07-22
EP0229155A4 EP0229155A4 (en) 1991-03-13

Family

ID=25003095

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860904524 Withdrawn EP0229155A4 (en) 1985-06-20 1986-06-16 Pharmaceutical complex and composition to inhibit hair loss

Country Status (3)

Country Link
EP (1) EP0229155A4 (fr)
JP (1) JPS63500517A (fr)
WO (1) WO1986007535A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008514A1 (fr) * 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions contenant du polyethylene glycol et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479903A (en) * 1982-08-23 1984-10-30 American Cyanamid Company Process for the preparation of N-allyl-O-alkyl thionocarbamates
US4482500A (en) * 1982-08-23 1984-11-13 American Cyanamid Company Process for the preparation of N-allyl-O-alkyl thionocarbamates
US4440783A (en) * 1983-02-24 1984-04-03 Bernard Weiss Composition for repelling animals from garbage and the like
US4524178A (en) * 1983-06-09 1985-06-18 The Dow Chemical Company Compositions of unsaturated polyesters or polyesteramides and efficient flexibilizers therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents have been disclosed. *
See also references of WO8607535A1 *

Also Published As

Publication number Publication date
EP0229155A4 (en) 1991-03-13
JPS63500517A (ja) 1988-02-25
WO1986007535A1 (fr) 1986-12-31

Similar Documents

Publication Publication Date Title
EP0142830B1 (fr) Composition réduisant la propagation du sébum
US4857302A (en) Solubilized benzoyl peroxide and cosmetic solution including solubilized benzoyl peroxide
JPH0676330B2 (ja) スキンケア組成物
EP0085334A2 (fr) Compositions topiques à bonne adhérence à la peau
FR2665705B1 (fr) Nouveaux derives fluores amphiphiles a structure telomere, leur procede de preparation et leur utilisation dans des preparations a usage biomedical.
FR2421889A1 (fr) Nouveaux derives d'acide thiazolidinecarboxylique-4 utiles comme medicaments antihypertenseurs et procedes pour leur preparation
US5210251A (en) Ester-modified silicone derivative and a cosmetic composition containing the same
US4985237A (en) Benzylidene compounds, cosmetic compositions containing the same and ultraviolet absorber comprising the same
US4428885A (en) Esterification reaction products
JP5488121B2 (ja) 経皮吸収促進及び/又は保湿性向上作用を示す剤、並びに化粧料
US4661519A (en) Method for dermatological application
FR2445329A1 (fr) Derives du 11-bromo-14-oxo-15-hydroxy-imino-e-homo-eburnane, leur preparation et leur utilisation comme medicament
EP0229155A1 (fr) Complexe pharmaceutique et composition pour empecher la chute descheveux
US5352696A (en) Quaternary nitrogen-containing vitamin E derivatives and uses thereof
JPH04169511A (ja) ニキビ用化粧料
DE69018730D1 (de) Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
WO2001051530A1 (fr) Agent antimicrobien faiblement irritant a masse moleculaire elevee
EP0090378A1 (fr) Composition contenant l'acide isoprénylcarboxylique pour l'application externe
FR2456101A1 (fr) Derives dihalogenes geminaux de pyrimidin-4-one condensees, procede pour leur preparation et compositions pharmaceutiques les contenant
JPH0632710A (ja) 皮膚外用剤
FR2366289A1 (fr) Nouveaux derives de l'imidazo(5,1-a)isoquinoleine, leur preparation et leur application comme medicaments
JPH01249885A (ja) 脂質の酸化防止剤
WO1988006878A1 (fr) Composition pharmaceutique contenant des esters d'acide benzoique et kit
JPS62195316A (ja) 皮膚料
FR2375192A1 (fr) Peptides contenant de la phenylglycine utiles comme medicaments, procede pour leur preparation et compositions pharmaceutiques en contenant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870821

A4 Supplementary search report drawn up and despatched

Effective date: 19910122

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900703

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DARKO, LASZLO, L.